A novel approach to safer glucocorticoid receptor-targeted anti-lymphoma therapy via REDD1 (Regulated in development and DNA damage 1) inhibition

Glucocorticoids are widely used for therapy of hematological malignancies. Unfortunately, chronic treatment with glucocorticoids commonly leads to adverse effects including skin and muscle atrophy and osteoporosis. We found recently that REDD1 (regulated in development and DNA damage 1) plays centra...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Lesovaya, Ekaterina A., Savinkova, Alena V., Morozova, Olga V., Lylova, Evgeniya S., Zhidkova, Ekaterina M., Kulikov, Evgeny P., Kirsanov, Kirill I., Klopot, Anna, Baida, Gleb, Yakubovskaya, Marianna G., Gordon, Leo I., Readhead, Ben, Dudley, Joel T., Budunova, Irina
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7875139/
https://ncbi.nlm.nih.gov/pubmed/32546661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-1111
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi